Enveric Biosciences Secures New U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series
Enveric Biosciences Inc ENVB
$1.50
▼ -2.91%
($-0.05)
🎈 Low Float
Open
$1.52
Prev Close
$1.55
Day Range
$1.48 – $1.53
52W Range
$1.17 – $13.25
Market Cap
$6.71M
Beta
1.29
EPS (TTM)
$-11.15
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2009-07-21 |
| Shares Out. | 3,680,000 |
| Website | enveric.com/ ↗ |
| Phone | 13026587581 |
| Employees | 6 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$3.0M |
| Free Cash Flow | -$8.6M |
| Total Assets | $8.9M |
| Total Liabilities | $861,475 |
| Equity | $8.1M |
About Enveric Biosciences Inc
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.
Enveric Biosciences Inc is a publicly traded company under the ticker symbol ENVB on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
7 analysts (2026-02-01)